Explore more
Lilly, Novo Nordisk and Zepbound
Digest more
A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while AstraZeneca leads on invention.
On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even in times of uncertainty. He pointed out that earnings are once again playing a significant role in driving market behavior.
Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, predicted that though Trump had spared the industry with tariffs, that wouldn't last much longer.
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves. Qatar pushes back on reports of $400M Boeing jet gift to Trump
The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult diseases.
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the workforce-talent pipeline.
Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation and workforce development.
Roche envisions its Indianapolis site as a “major hub” for the manufacturing of its continuous glucose monitoring systems. The news comes on the heels of an announced $700 million investment in North Carolina.
The new research and development site will combine research, process development and clinical trial manufacturing capabilities into one plant.
Feedback